These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 18054388)

  • 1. The immunogenic CBD1 peptide corresponding to the caveolin-1 binding domain in HIV-1 envelope gp41 has the capacity to penetrate the cell membrane and bind caveolin-1.
    Benferhat R; Sanchez-Martinez S; Nieva JL; Briand JP; Hovanessian AG
    Mol Immunol; 2008 Apr; 45(7):1963-75. PubMed ID: 18054388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 neutralizing antibodies elicited by the candidate CBD1 epitope vaccine react with the conserved caveolin-1 binding motif of viral glycoprotein gp41.
    Rey-Cuillé MA; Svab J; Benferhat R; Krust B; Briand JP; Muller S; Hovanessian AG
    J Pharm Pharmacol; 2006 Jun; 58(6):759-67. PubMed ID: 16734977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The caveolin-1 binding domain of HIV-1 glycoprotein gp41 (CBD1) contains several overlapping neutralizing epitopes.
    Benferhat R; Krust B; Rey-Cuillé MA; Hovanessian AG
    Vaccine; 2009 Jun; 27(27):3620-30. PubMed ID: 19464543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CBD1 peptide corresponding to the caveolin-1 binding domain of HIV-1 glycoprotein gp41 elicits neutralizing antibodies in cynomolgus macaques when administered with the tetanus T helper epitope.
    Benferhat R; Martinon F; Krust B; Le Grand R; Hovanessian AG
    Mol Immunol; 2009 Feb; 46(4):705-12. PubMed ID: 19010547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of nonpolar substitutions of the conserved Phe11 in the fusion peptide of HIV-1 gp41 on its function, structure, and organization in membranes.
    Pritsker M; Rucker J; Hoffman TL; Doms RW; Shai Y
    Biochemistry; 1999 Aug; 38(35):11359-71. PubMed ID: 10471286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion.
    Dimitrov AS; Rawat SS; Jiang S; Blumenthal R
    Biochemistry; 2003 Dec; 42(48):14150-8. PubMed ID: 14640682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection.
    Hovanessian AG; Briand JP; Said EA; Svab J; Ferris S; Dali H; Muller S; Desgranges C; Krust B
    Immunity; 2004 Nov; 21(5):617-27. PubMed ID: 15539149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of fusion peptides from HIV gp41 with membranes: a time-resolved membrane binding, lipid mixing, and structural study.
    Buzón V; Padrós E; Cladera J
    Biochemistry; 2005 Oct; 44(40):13354-64. PubMed ID: 16201760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural analysis and assembly of the HIV-1 Gp41 amino-terminal fusion peptide and the pretransmembrane amphipathic-at-interface sequence.
    Lorizate M; de la Arada I; Huarte N; Sánchez-Martínez S; de la Torre BG; Andreu D; Arrondo JL; Nieva JL
    Biochemistry; 2006 Dec; 45(48):14337-46. PubMed ID: 17128972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The binding of HIV-1 gp41 membrane proximal domain to its mucosal receptor, galactosyl ceramide, is structure-dependent.
    Yu H; Alfsen A; Tudor D; Bomsel M
    Cell Calcium; 2008 Jan; 43(1):73-82. PubMed ID: 17553560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caveolin scaffolding region and the membrane binding region of SRC form lateral membrane domains.
    Wanaski SP; Ng BK; Glaser M
    Biochemistry; 2003 Jan; 42(1):42-56. PubMed ID: 12515538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the interacting domain of the HIV-1 fusion peptide with the transmembrane domain of the T-cell receptor.
    Cohen T; Pevsner-Fischer M; Cohen N; Cohen IR; Shai Y
    Biochemistry; 2008 Apr; 47(16):4826-33. PubMed ID: 18376816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A leucine zipper-like sequence from the cytoplasmic tail of the HIV-1 envelope glycoprotein binds and perturbs lipid bilayers.
    Kliger Y; Shai Y
    Biochemistry; 1997 Apr; 36(17):5157-69. PubMed ID: 9136877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid modulation of membrane-bound epitope recognition and blocking by HIV-1 neutralizing antibodies.
    Huarte N; Lorizate M; Kunert R; Nieva JL
    FEBS Lett; 2008 Nov; 582(27):3798-804. PubMed ID: 18930052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
    Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
    Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.
    Veiga AS; Pattenden LK; Fletcher JM; Castanho MA; Aguilar MI
    Chembiochem; 2009 Apr; 10(6):1032-44. PubMed ID: 19283693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quaternary protein mimetics of gp41 elicit neutralizing antibodies against HIV fusion-active intermediate state.
    Sadler K; Zhang Y; Xu J; Yu Q; Tam JP
    Biopolymers; 2008; 90(3):320-9. PubMed ID: 18338371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conformational study of fragments of envelope proteins (gp120: 254-274 and gp41: 519-541) of HIV-1 by NMR and MD simulations.
    Kanyalkar M; Srivastava S; Saran A; Coutinho E
    J Pept Sci; 2004 Jun; 10(6):363-80. PubMed ID: 15214441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membrane-induced conformational change during the activation of HIV-1 gp41.
    Kliger Y; Peisajovich SG; Blumenthal R; Shai Y
    J Mol Biol; 2000 Aug; 301(4):905-14. PubMed ID: 10966795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Membrane-specific antibodies induced by liposomes can simultaneously bind to HIV-1 protein, peptide, and membrane lipid epitopes.
    Beck Z; Karasavvas N; Matyas GR; Alving CR
    J Drug Target; 2008 Aug; 16(7):535-42. PubMed ID: 18686123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.